In conclusion, in this open-label extension study, ulotaront, one of the first of a new class of TAAR1 agonists, in the daily dose range of 25–75 mg, was generally safe, well-tolerated, and effective in the long-term treatment of patients with schizophrenia. This evidence concerns the gene TAAR1 and schizophrenia.